Rein Posthuma

1 month ago | publications.ersnet.org | Jorine Hartman |Marnix Jonker |Rein Posthuma |Lowie E.G.W. Vanfleteren

IntroductionBronchoscopic lung volume reduction using endobronchial valves (EBV) has been shown to provide clinical benefits for patients with emphysema including improvements in lung function, exercise capacity, dyspnoea severity and quality of life [1]. Recently, there has been increased attention on the potential extrapulmonary effects of this treatment.

Jan 23, 2025 | publications.ersnet.org | Rein Posthuma |Anouk W. Vaes |Jorine Hartman |Martijn A. Spruit

AbstractBronchoscopic lung volume reduction using one-way endobronchial valves (BLVR-EBV) improves exercise capacity and quality of life in patients with severe emphysema. However, its effect on symptoms of fatigue, anxiety and depression is unclear. Furthermore, if the combination of pulmonary rehabilitation (PR) and BLVR-EBV yields additional impact on these symptoms remains unknown.

Feb 17, 2024 | resmedjournal.com | Rein Posthuma |Jorine Hartman |Martijn A. Spruit |Dirk-Jan Slebos |Lowie E.G.W. Vanfleteren |Anouk W. Vaes

Patients with advanced emphysema eligible for bronchoscopic lung volume reduction (BLVR) using endobronchial valves (EBV) are characterized by severe static lung hyperinflation, which can be considered a treatable trait. Other treatable traits (TTs), which are assumed to be present in this highly selected patient group, have not been studied in detail nor how they may affect health-related quality of life (HRQL).